Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18364766 | 0.86 | ATM (0.48) | ATMHCAR2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL18364244 | 0.85 | ATM (0.40) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL18364181 | 0.82 | HCAR2 (0.43) | ATMHCAR2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL18364178 | 0.82 | HCAR2 (0.48) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL18364149 | 0.82 | HCAR2 (0.45) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL18364899 | 0.77 | ATM (0.55) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL18364384 | 0.74 | ATM (0.45) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL18364170 | 0.74 | EPHX1 (0.47) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL18364790 | 0.73 | EPHX1 (0.47) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL13051497 | 0.73 | TSHR (0.52) | ATMEPHX2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170008835-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008835-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008835-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | ATM 4406/4885HCAR2 290/4885CHRNB2 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.